January 15, 2026 · Phase 2 readout
TNGX Phase 2 readout: a negative outcome, -5.6%
On January 15, 2026, TNG260 — Tango Therapeutics, Inc. (Non Small Cell Lung Cancer) reached its Phase 2 readout. The result was a negative outcome, and the stock moved -5.6% in the window around the event. It had already run +19.0% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.
The move
$12.39
1d before
$11.69
Event day
$13.01
1d after
$12.51
5d after
Pre-catalyst setup
+19.0%
30-day run-up
11699%
30-day volatility
1.6×
volume spike